Wang Jian, Zhang Yong, Wan Haiyun, Dong Nian, Bao Liannin, Sun Xiaoqong, Xu Menglin, Wang Xiangdong
Zhongshan Hospital, Fudan University Medical School, Shanghai Institute of Clinical Bioinformatics, Shanghai, China.
Cancer Metastasis Rev. 2015 Jun;34(2):333-45. doi: 10.1007/s10555-015-9568-y.
Lung cancer is the most common cancer and becomes the leading cause of cancer mortality. Genetic and epigenetic alterations and variations are important to identify target genes in lung cancer and demonstrate the potential association of the chromosome 7 aberration with tumorigenesis. The present article integrated the independent and scattered global datasets to detect significant genes, co-expressed, type-special and stage-special genes in lung cancer with a special focus on chromosome 7 with bioinformatics analysis methods. About 60, 214, 26, or 49 up-regulated type-special genes, and 67, 35, 114, or 141 down-regulated type-special genes were identified in adenocarcinoma (ADC), squamous cell carcinoma (SCC), large cell carcinoma (LCC) or small-cell lung cancer (SCLC), respectively. About 5, 2, 8, or 1 stage-specific genes were up-regulated, while 23, 8, 2, or 90 stage-specific genes were down-regulated in ADC at stage I, II, III, or IV, respectively. Two stage-specific genes were significantly up-regulated in SCC at stage II, while 2 or 18 stage-specific genes in SCC at stage I or III were down-regulated, respectively. Lung cancer prognostic prediction rates of subtype- or stage-specific genes were further evaluated. The present study globally analyzed and identified subtype- or stage-specific target genes of lung cancer on chromosome 7 by combining 16 GSE datasets for the first time, although there are still needs to furthermore validate the clinical values of those identified genes in a large population of patients with lung cancer.
肺癌是最常见的癌症，并且成为癌症死亡的主要原因。基因和表观遗传改变及变异对于识别肺癌中的靶基因以及证明7号染色体畸变与肿瘤发生之间的潜在关联至关重要。本文整合了独立且分散的全球数据集，采用生物信息学分析方法来检测肺癌中的显著基因、共表达基因、类型特异性基因和阶段特异性基因，特别关注7号染色体。在腺癌（ADC）、鳞状细胞癌（SCC）、大细胞癌（LCC）或小细胞肺癌（SCLC）中，分别鉴定出约60、214、26或49个上调的类型特异性基因，以及67、35、114或141个下调的类型特异性基因。在I期、II期、III期或IV期的ADC中，分别有5、2、8或1个阶段特异性基因上调，而有23、8、2或90个阶段特异性基因下调。在II期的SCC中有两个阶段特异性基因显著上调，而在I期或III期的SCC中分别有2个或18个阶段特异性基因下调。进一步评估了肺癌亚型或阶段特异性基因的预后预测率。本研究首次通过整合16个GSE数据集，对7号染色体上肺癌的亚型或阶段特异性靶基因进行了全面分析和鉴定，尽管仍需要在大量肺癌患者中进一步验证这些鉴定出的基因的临床价值。
